Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Protagonist Therapeutics, Inc. $PTGX

Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 26.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 114,036 shares of the company’s stock after acquiring an additional 23,719 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Protagonist Therapeutics were worth $9,960,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PTGX. Smartleaf Asset Management LLC raised its holdings in shares of Protagonist Therapeutics by 11.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock valued at $91,000 after purchasing an additional 146 shares in the last quarter. Farther Finance Advisors LLC grew its stake in shares of Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares in the last quarter. Parkman Healthcare Partners LLC grew its stake in shares of Protagonist Therapeutics by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 61,849 shares of the company’s stock worth $4,109,000 after purchasing an additional 253 shares in the last quarter. Guggenheim Capital LLC increased its holdings in Protagonist Therapeutics by 1.6% in the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock valued at $1,062,000 after buying an additional 303 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in Protagonist Therapeutics by 138.9% in the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after buying an additional 314 shares during the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PTGX has been the subject of a number of recent analyst reports. Barclays lifted their price target on Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, March 19th. The Goldman Sachs Group increased their price objective on Protagonist Therapeutics from $65.00 to $95.00 and gave the company a “neutral” rating in a report on Tuesday, March 3rd. Jefferies Financial Group reissued a “buy” rating and set a $121.00 target price on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. JPMorgan Chase & Co. boosted their target price on Protagonist Therapeutics from $95.00 to $106.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. Finally, Leerink Partners upped their price target on Protagonist Therapeutics from $107.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, March 19th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $108.15.

Insiders Place Their Bets

In related news, CFO Asif Ali sold 1,750 shares of the company’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $105.47, for a total value of $184,572.50. Following the completion of the sale, the chief financial officer directly owned 59,003 shares of the company’s stock, valued at $6,223,046.41. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Harold E. Selick sold 24,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $105.00, for a total value of $2,520,000.00. Following the transaction, the director owned 60,845 shares in the company, valued at $6,388,725. This represents a 28.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 213,486 shares of company stock worth $20,129,058. Corporate insiders own 4.90% of the company’s stock.

Protagonist Therapeutics Price Performance

Shares of PTGX opened at $100.00 on Monday. Protagonist Therapeutics, Inc. has a 1-year low of $41.28 and a 1-year high of $107.84. The stock has a market cap of $6.38 billion, a PE ratio of -48.78 and a beta of 2.12. The firm has a fifty day moving average price of $97.15 and a 200 day moving average price of $88.30.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The company had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. As a group, equities analysts expect that Protagonist Therapeutics, Inc. will post 1.02 EPS for the current fiscal year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.